Epoprostenol up-regulates serum adiponectin level in patients with systemic sclerosis: therapeutic implications

Stochmal, Anna; Czuwara, Joanna; Zaremba, Michał; Rudnicka, Lidia

doi:10.1007/s00403-020-02172-0

Cited by 4 publications

(6 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A single study reported correlations with signs of vasculopathy, as patients with reduced adiponectin concentrations showed a higher prevalence of pitting scars [ 203 ]. Finally, adiponectin was shown to significantly increase in SSc patients after treatment with epoprostenol, a prostaglandin analogue with powerful vasodilator activity [ 208 ].…”

Section: Cytokinesmentioning

confidence: 99%

Section: Cytokinesmentioning

confidence: 99%

“…Resistin, predominately secreted by immune cells after stimulation with TNFα, IL-6, and IL-12, exerts pro-inflammatory properties and has been involved in the pathologenesis of different inflammatory diseases [ 208 ]. Resistin is also able to induce an angiogenic response in ECs by enhancing ET-1 production [ 208 ]. In a preliminary study, circulating resistin levels were found to be similar between SSc and controls and, when patients were classified into two groups (i.e., patients with high or normal resistin levels on the bases of healthy control levels), no difference between these two groups was demonstrated for the frequency of cutaneous vascular manifestations, including pitting scars, telangiectasia, and nailfold bleeding [ 215 ].…”

Section: Cytokinesmentioning

confidence: 99%

“…A subsequent meta-analysis also found that resistin was not significantly different between SSc patients and healthy subjects [ 201 ]. Conversely, following studies demonstrated an increase in resistin values in SSc patients with respect to controls [ 143 , 197 , 208 , 216 , 217 ], with higher resistin in patients with DUs [ 213 ], in patients developing new DUs after a 52-weeks follow-up [ 217 ], and in those with PAH [ 143 ]. In another study, no association was found between resistin and nailfold capillaroscopy characteristics or DUs [ 216 ].…”

Section: Cytokinesmentioning

confidence: 99%

See 3 more Smart Citations

Current Trends in Vascular Biomarkers for Systemic Sclerosis: A Narrative Review

Fioretto

Rosa

Matucci‐Cerinic

et al. 2023

IJMS

View full text Add to dashboard Cite

Systemic sclerosis (SSc, scleroderma) is a multifaceted rare connective tissue disease whose pathogenesis is dominated by immune dysregulation, small vessel vasculopathy, impaired angiogenesis, and both cutaneous and visceral fibrosis. Microvascular impairment represents the initial event of the disease, preceding fibrosis by months or years and accounting for the main disabling and/or life-threatening clinical manifestations, including telangiectasias, pitting scars, periungual microvascular abnormalities (e.g., giant capillaries, hemorrhages, avascular areas, ramified/bushy capillaries) clinically detectable by nailfold videocapillaroscopy, ischemic digital ulcers, pulmonary arterial hypertension, and scleroderma renal crisis. Despite a variety of available treatment options, treatment of SSc-related vascular disease remains problematic, even considering SSc etherogenity and the quite narrow therapeutic window. In this context, plenty of studies have highlighted the great usefulness in clinical practice of vascular biomarkers allowing clinicians to assess the evolution of the pathological process affecting the vessels, as well as to predict the prognosis and the response to therapy. The current narrative review provides an up-to-date overview of the main candidate vascular biomarkers that have been proposed for SSc, focusing on their main reported associations with characteristic clinical vascular features of the disease.

show abstract

Section: Cytokinesmentioning

confidence: 99%

Section: Cytokinesmentioning

confidence: 99%

Section: Cytokinesmentioning

confidence: 99%

Section: Cytokinesmentioning

confidence: 99%

See 2 more Smart Citations

Current Trends in Vascular Biomarkers for Systemic Sclerosis: A Narrative Review

Fioretto

Rosa

Matucci‐Cerinic

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Beraprost did not prevent development of DU ( 119 ) and had little effect on hemodynamic parameters in SSc-PAH ( 120 ). Conversely, epoprostenol improved clinical status and hemodynamic parameters ( 121 , 122 ), and increased serum levels of adiponectin ( 123 ), suggesting effects on vascular function ( 124 ) and on adipose tissue metabolic pathways ( 123 ). Treprostinil improved cutaneous blood flow ( 125 , 126 ) and healing of DU ( 127 ), but recent studies failed to show changes in vascular, angiogenic and inflammatory biomarkers ( 128 ).…”

Section: Prostanoidsmentioning

confidence: 99%

Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies

Zanin-Silva

Santana-Gonçalves

Kawashima-Vasconcelos

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Systemic Sclerosis (SSc) is an autoimmune disease marked by dysregulation of the immune system, tissue fibrosis and dysfunction of the vasculature. Vascular damage, remodeling and inadequate endothelial repair are hallmarks of the disease. Since early stages of SSc, damage and apoptosis of endothelial cells (ECs) can lead to perivascular inflammation, oxidative stress and tissue hypoxia, resulting in multiple clinical manifestations. Raynaud's phenomenon, edematous puffy hands, digital ulcers, pulmonary artery hypertension, erectile dysfunction, scleroderma renal crisis and heart involvement severely affect quality of life and survival. Understanding pathogenic aspects and biomarkers that reflect endothelial damage in SSc is essential to guide therapeutic interventions. Treatment approaches described for SSc-associated vasculopathy include pharmacological options to improve blood flow and tissue perfusion and, more recently, cellular therapy to enhance endothelial repair, promote angiogenesis and heal injuries. This mini-review examines the current knowledge on cellular and molecular aspects of SSc vasculopathy, as well as established and developing therapeutic approaches for improving the vascular compartment.

show abstract

Feasibility of adipose-derived therapies for hair regeneration: Insights based on signaling interplay and clinical overview

Guo

Chen

et al. 2023

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Epoprostenol up-regulates serum adiponectin level in patients with systemic sclerosis: therapeutic implications

Cited by 4 publications

References 62 publications

Current Trends in Vascular Biomarkers for Systemic Sclerosis: A Narrative Review

Current Trends in Vascular Biomarkers for Systemic Sclerosis: A Narrative Review

Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies

Feasibility of adipose-derived therapies for hair regeneration: Insights based on signaling interplay and clinical overview

Contact Info

Product

Resources

About